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SUMMARY 
Naturally occurring mutations in hypoxanthine-guanine phosphoribosyltransferase (HPRT) have been identified by 
amino acid sequencing, cDNA cloning, and direct nucleotide sequencing of PCR-amplified transcripts. To determine the 
effect these mutations have on the catalytic properties of the molecule, knowledge of the three-dimensional structure of 
HPRT is required. A prerequisite for this, however, is the availability of a large amount of purified product for crystalliza- 
tion and x-ray diffraction analysis. For these reasons we have developed an effective means of producing high levels of 
human HPRT in Escherichia cdi using the expression cassette PCR. By taking advantage of a T7 polymerase/promoter 
system, we have expressed both normal and variant human hprt sequences in E. cd. The proteins synthesized from 
these sequences are immunologically and enzymatically active, and are physically indistinguishable from the HPRT in 
B-lymphoblasts derived from normal and three HPRT-deficient subjects. 
INTRODUCTION 
Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) is a purine salvage enzyme which catalyzes the 
formation of GMP and IMP from guanine and hypoxan- 
thine, respectively, using PRPP as the phosphoribosyl 
donor. A partial deficiency of this cytosolic enzyme can 
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cause hyperuricemia, hyperuricaciduria, uric acid nephro- 
lithiases, and in extreme cases, neurologic dysfunction 
(Kelley et al., 1967). Manifestations of complete defi- 
ciency, or the Lesch-Nyhan syndrome, include retarded 
growth, spasticity, choreathetoid movements, a tendency 
to self-mutilate and, in most cases, mental retardation 
(Lesch and Nyhan, 1964; Seegmiller et al., 1967). The 
pathophysiologic basis for these neurologic effects re- 
mains unclear. 
The primary structure of human HPRT has been de- 
fined (Wilson et al., 1982b). The mature enzyme consists 
of 217 aa with the N-terminal Met removed and the pen- 
ultimate Ala acetylated (Wilson et al., 1982b). Regions of 
a-helix, p-sheet, and other secondary structure motifs 
have been predicted for the molecule based on this pri- 
mary sequence information. Inferences on the tertiary 
structure of the molecule, with regards to PRPP and pu- 
rine-binding sites, have been made based on comparisons 
of conserved structures in other PRTases and by defining 
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mutations in kinetic variants (Hershey and Taylor, 1986; 
Argos et al., 1983). Based on these types of studies, aa 
130-l 50 and 140-210 have been predicted to be involved 
in purine and PRPP binding, respectively. Both areas 
contain stretches of aa sequence which is highly con- 
served from E. coli to mammals. As noted, substitutions 
in these regions are usually deleterious to enzyme 
function. 
The actual role of these putative binding domains, 
however, can only be addressed by x-ray crystallographic 
analysis of normal and mutant enzymes, a major prere- 
quisite of which is large amounts of purified protein. As 
demonstrated in this report, we have addressed this by 
developing a novel ECPCR method for enhanced transla- 
tion of human hprt sequences in E. coli. This technique 
was effective in producing high levels of both normal and 
mutant HPRT for subsequent purification. 
EXPERIMENTAL AND DISCUSSION 
(a) Construction of an expression cassette 
The PCR primers used to generate the expression cas- 
sette for hprt were synthesized at the Oligonucleotide 
Synthesis Core Facility, University of Michigan. The 5’ 
primer contains an EcoRI site, a T7 phage gene 10 (T&O) 
leader sequence (Olins et al., 1988), an SD consensus se- 
quence, and 20 bp of normal human hprt coding sequence 
beginning with the A of the ATG start codon (Fig. 1). The 
3’ primer consists of an EcoRI site 3’ of the terminal 15 bp 
of HPRT-coding sequence (Fig. 1). Five pg of each primer, 
100 ng of hprt template in M 13mp 18, and 1 mM dNTPs, 
were combined in 1 x Tuq buffer (2 mM MgClJlO mM 
KCl/lO mM Tris pH 8.3/l mM DTT) and heated to 94°C 
for 3 min. After the addition of 1 unit Tuq DNA polymer- 
ase (Ampli-Taq, Perkin Elmer/Cetus, Norwalk, CT) the 
mixture was subjected to five cycles of 94”C, 1 min, 22”C, 
1 min, 72”C, 2 min and then 30 cycles of 94”C, 1 min, 
72”C, 2 min. The PCR reaction pkoducts were cut with 
EcoRI (Bethesda Research Laboratories) and purified on 
a QiagenTM . tip-5. The hprt expression cassettes for mutant 
sequences were made by performing the PCR on cDNAs 
generated by reverse transcribing 1 pg total RNA isolated 
from B-lymphoblast cell lines derived from patients K.C., 
P.C., and D.B., using previously described techniques 
(Table I; Davidson et al., 1989b). Conditions for amplify- 
ing and purifying mutant sequences were the same as 
those used for the wt template. 
Expression cassettes for normal and mutant sequences 
were cloned into EcoRI-cut pSP72 (Promega, Madison, 
WI) downstream from the T7 promoter, and used to 
transform E. coli DH5a (Bethesda Research Laborato- 
ries). All expression plasmids were subjected to dideoxy- 
nucleotide sequencing to insure authenticity of sequence. 
The wt clone pSPSDE3, and variant clones pSPPC24, 
pSPKC4 and pSPDB1 (representing HPRTAshville, 
HPRTA,, Arbor, and HPRT,,,,,,, respectively) were then 
used to transform BL21(DE3) for high-level production 
of human HPRT (Olins et al., 1988). The plasmids are 
described in detail in Table II. 
(b) Time course of production of human HPRT in 
Escherichia coli 
Fig. 2 is an SDS-PAGE gel of aliquots from a time 
course of induction of BL21(DE3)[pHPSDE3]. The pro- 
duction of a 24-kDa protein is evident in as little as 30 
min post induction, and continues for up to 8 h (lanes 
2-7). When the induction is allowed to continue for 24 h, 
there is little change in the relative amount of protein 
produced as compared to the 8 h time point (data not 
shown). As seen in lanes 8 and 9, there is no concomittant 
increase in the expression of a 24-kDa protein when 
pSP72 in BL21(DE3) is used; only the T7 polymerase 
subunits are induced. Note that expression of these sub- 
units in the HPRT-expressing plasmids appears to be 
repressed, presumably due to the enhanced translation. 
Immunoblotting was done using anti-human HPRT 
antibody to identify the overexpressed 24-kDa protein. 
As evident in lane 1 of Fig. 3, low levels of human HPRT 
are expressed before the addition of IPTG. This is pre- 
sumably due to the fact that the lacUV5 promoter driving 
transcription of the T7 polymerase gene is not tightly 
repressed, even in the absence of IPTG. However, when 
IPTG is added, there is a large increase in the level of 
HPRT expressed by pHPSDE3 (lanes 2-4). Human 
HPRT is also evident in lane 6, which is 
BL21(DE3)[pHPSDE5]. This construct contains human 
hprt cloned in the opposite orientation to the T7 pro- 
moter. In this context, low-level synthesis of HPRT may 
occur as a result of transcription off an upstream pro- 
AGA GAA TTC AAT AAT l-l-l- G’IT TAA CTT TAA GAA GGA GAT ATA TCC 
Em RI Epsilon SD 
ATG GCG ACC CGC ACC CGC AGC CCT GGC GTC 
Human hprr Sequence 
Fig. 1. Expression cassette for expressing human hprt in E. cofi. The cassette contains an EcoRI cloning site, the E (epsilon) sequence from T7 
bacteriophage gene 10 (Olins et al., 1988), and an SD sequence. The sequences which overlap with human hprt cDNA sequences are indicated (bold). 
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TABLE I 
HPRT: aa substitutions and physical properties of HPRT variants 
Cell line Variant The aa substitutions Physical properties 
D.B. London Serlio+Leu increased anodal migration on SDS-PAGE 
K.C. Ann Arbor Ile13Z-+Met normal migration on SDS-PAGE and nondenaturing PAGE 
P.C. Ashville Aspzol +Gly decreased anodal migration on nondenaturing PAGE 






Plasmids of variant hprt cDNAs 
Varianta The nt substitutionb Plasmid” 
wt pSPSDE3 
D.B. C329-+T pSPDB1 
K.C. Tag9+G pSPKC4 
PC. A602-tG pSPPC24 
“See Table 1 for details regarding variants. 
‘Substitution of nt with respect to wt sequence. 
‘The plasmid backbone is pSP72 (Promega, Madison, WI). 
HPRT 
30- 
Fig. 2. Time course of synthesis of human HPRT in E. coli. Human 
HPRT was produced by the addition of 0.4 mM IPTG to cultures of 
BL21(DE3)[pHPSDE3] when Asoo reached 0.4. Aliquots (1 ml) were 
removed at 0, 30 min, 1, 2, 4, and 8 h (lanes 2-7, respectively), centri- 
fuged 3 min, 14 000 x g, washed in 1 ml Hanks Balanced Salt Solution 
(HBSS, Gibco) divided into two 500 ml aliquots and centrifuged again 
for 3 min at 14 000 x g. One cell pellet was resuspended in Laemmli 
SDS-PAGE buffer and a portion analyzed by 0.1% SDS-12% PAGE. 
Note the rapid expression of human HPRT (large arrow). IPTG was 
also added to cultures of BL21(DE3)[pSP72]. These lysates were ana- 
lyzed 1 and 8 h post induction (lanes 8 and 9). Lane 1, M, markers. 
Molecular size (in kDa) are indicated on the left margin. 
moter (for example p-lactamase) in conjunction with the 
strong translational enhancer sequences. In the parent 




Fig. 3. Immunoblot of human HPRT produced in E. co/i. Cultures of 
BL21(DE3)[pHPSDE3] were analyzed for the presence of human 
HPRT at 0, 30 min, 1, and 2 h post induction (lanes l-4). Protein was 
blotted onto PVDF membranes (Millipore), blocked 2 h at room tem- 
perature with TNS/O.S% Tween-20 (TT buffer; TNS is 20 mM Tris pH 
7.5/500mM NaCI), washed (all washes and antibody dilutions were 
done in TT buffer unless otherwise indicated), incubated overnight with 
anti-human HPRT antibody at 4°C washed, incubated with goat-anti- 
rabbit antibody conjugated to alkaline phosphatase (Kirkegaard and 
Perry Laboratories, Inc., Gaithersburg, MD) for 2 h at room temper- 
ature, washed in TNS, and incubated with NBT/TIBS substrate (Kir- 
kegaard and Perry Laboratories). Lane 5 is of BL21(DE3)[pSPSDES] 
lysate in which the hprt cDNA is cloned antisense to the T7 promoter 
in pSP72. Lane 6 is lysate from BL21(DE3)[pSP72]. Cultures of 
BL21(DE3)[pSPSDES] and BL21(DE3)[pSP72] were harvested 4 h 
after induction. Lane 7 contains 4 ng of purified human HPRT, the 
lower limit for this detection system. Gel as in Fig. 2. MW, prestained 
molecular size markers (Amersham). Molecular sizes as in Fig. 2. Large 
arrow points to the human HPRT. 
(c) Purification of human HPRT from Esclrerichia coti 
Large-scale cultures (500-ml aliquots) of BL2 l- 
(DE3)[pHPSDE3] were grown, and the cells harvested 
and lysed as described. Xanthine was added to a concen- 
tration of 1 mM before column loading to reduce the bind- 
ing of E. coli xpt/gpt to the affinity sites. Bound human 
HPRT was eluted with buffer A containing 1 mM GMP, 
and the fractions containing the peak of human HPRT 
collected and concentrated. As seen in the SDS-PAGE gel 
in Fig. 4 (lane 2), the eluate contains more than 95% pure 
human HPRT. Initially, a molecular sieve column was 
included in the purification scheme, and was run before 
the affinity column. However, this did not significantly 
increase the purity of the final product (data not shown). 
(d) Production of mutant HPRT in Escherichia coli 
cDNAs were generated from three previously 
characterized human HPRT variants, HPRT,,, Arbor, 
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Fig. 4. Purllied human HPRT isolated from E. coli. For purificatton, 
single colonies were placed in 3 ml of LB broth containing 30 ug ampi- 
cillin/ml, allowed to grow to A,,,n of 0.4-0.6, and transferred to 500 ml 
LB broth. The culture was allowed to reach A,,,, of 0.4, after which 
IPTG was added to 0.4mM final concentration. Inductions ranged 
from 4 h to overnight for large scale cultures. After induction the cells 
were harvested, washed in buffer A, and resuspended in buffer A con- 
taining 10% glycerol. The suspension was lysed by French press, debris 
pelleted, and the remaining lysate brought to I mM xanthine. The lysate 
was then passed over a GMP-agarose affinity column (Sigma Biochemi- 
cals). The column was washed with buffer A (buffer A is SO mM Tris 
pH 7.4/25 mM KCljlO mM MgCl,/I mM DTT), and human HPRT 
eluted with I mM GMP in buffer A. Those fractions containing human 
HPRT were pooled, concentrated, and analyzed for purity by 0.1% 
SDS-12% PAGE followed by Coomassie staining. Molecular size 
in kDa are indicated on the left margin. 
HPRTAsh”ille, and HPRT,,,,,, (Table I), by reverse 
transcribing RNA isolated from B-lymphoblasts derived 
from patients K.C., P.C., and D.B., respectively, followed 
by ECPCR. The resultant expression cassettes were then 
cloned into pSP72 and transformed into BL21(DE3) 
as described. Colonies were induced for production of 
HPRT, and analyzed by SDS-PAGE and nondenaturing 
PAGE followed by activity gel assay. As noted in Table I, 
HPRT~ondon migrates more anodally than does normal 
HPRT in SDS-PAGE of B-lymphoblast lysates. This 
physical property is reproduced in pHPDB1, the expres- 
sion cassette representing this variant (Fig. 5A). Immu- 
noblotting confirmed that the faster migrating species was 
HPRT (Fig. 5B). The HPRT produced from pSDKC4 
and pSDPC21 exhibited normal migration on SDS- 
PAGE following induction with IPTG, consistent with 
the corresponding variant protein from B-lymphoblasts 
(data not shown). 
Fig. 5. Expression of HPRT,,,,,,, in E. coli. (Panel A) Cultures of 
BL2l(DE3)[pSPDBI] and BL21(DE3)[pSPSDE3] were induced, and 
lysates analyzed by SDS-PAGE (as in Fig. 2). The arrows denote the 
differences in migration between normal (N) and London (L) HPRTs. 
MW, rainbow markers (Amersham). Molecular sizes in kDa are 
indicated. (Panel B) Immunoblot of the SDS polyacrylamide gel in 
panel A. 
Lysates from induced cultures of pSDDB1, pSDKC4 
and pSDPC21 were also run on native gels and then 
assayed in situ for HPRT activity. As expected, protein 
synthesized from pSDKC4 had normal migration while 
pSDPC21 was less anodal than normal (Fig. 6). Again, 
these properties are consistent with those of the B-lym- 
phoblast proteins. 
The use of the T7 bacteriophage gene 10 translational 
enhancer sequences upstream from the required SD se- 
quence in the expression cassette greatly improved the 
expression of T7 promoter-driven sequences (Fig. 1). 
When expression cassettes were made containing only the 
normal hprt cDNA construct plus SD sequences, the pro- 
duction of HPRT was minimal (data not shown). Indeed, 
the presence of human HPRT was visualized only by 
nondenatured PAGE/activity assay in lysates from these 
cultures, and not by SDS PAGE. Additionally, we saw 
only variable levels of low expression when this cassette 
was cloned downstream from a heat-inducible tat pro- 
moter (data not shown). However, the tat promoter sys- 
tem was not tried in conjunction with the strong 
translational enhancer sequences. 
An additional consideration when using strong transla- 
tional enhancer sequences is the ‘leakiness’ of the pro- 
moter driving T7 polymerase. As evident in Fig. 3, human 
HPRT was synthesized, albeit at low levels, even in the 
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100 kDa 
Fig. 6. Analysis of synthesised proteins by native 6% PAGE and activ- 
ity assay. Cultures containing the variant hprt expression cassettes were 
induced for 4 h, harvested, and aliquots resuspended in lysis buffer (20 
ug lysozyme/ml in IO ml MgCl,/20 mM KCljSO mM Tris pH 7.4), incu- 
bated for 30 min at room temperature, and centrifuged at 14 000 x g for 
5 min. Non-denatured lysates were run on 6% polyacrylamide gels and 
assayed in situ for human HPRT activity using previously described 
techniques (Davidson et al., 1989a). Lanes: 1, 5 ug of protein from 
GM558 lysate, a B-lymphoblast line derived from a normal male; 2-5, 
E. coli BL21(DE3) cells carrying: pSPDB1, pSPKC4, pSPPC24, and 
pSPSDE3, respectively (described in Table II). 
absence of IPTG. If the gene of interest is deleterious to 
cell viability such an enhancer may be counter- 
productive. Based on this, a variety of combinations of 
translation enhancer/promoter systems may need to be 
tried to maximize protein production. 
The one-step purification scheme for obtaining human 
HPRT is a dramatic improvement over that required to 
isolate purified human HPRT from erythrocyte lysates 
(Wilson et al., 1982b), making this an attractive alterna- 
tive for obtaining large amounts of the purified enzyme 
for crystallographic analysis. Furthermore, one of the 
variant proteins chosen for this study, HPRT,,,,,,, has 
been purified in small amounts from erythrocytes using 
a GMP-affinity column (Wilson et al., 1983). Crystalliza- 
tion and analysis of these two proteins alone will enable 
us to understand the elevated (sixfold) K, for hypoxan- 
thine in this variant. 
(e) Conclusions 
ECPCR done with expression cassettes containing 
strong translational enhancer sequences enabled us to 
synthesize and purify active human HPRT in E. coli. In 
addition, variant sequences were expressed, with the re- 
sultant proteins exhibiting physical properties indistin- 
guishable from their B-lymphoblast counterparts. These 
results complete an important preliminary step towards 
understanding the enzymology of HPRT, namely, pro- 
ducing large quantities of the protein for crystal growth, 
diffraction analysis, and three-dimensional structure de- 
termination. 
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